Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investors - CNBC


8/24/2025

Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investors  CNBCIs Orforglipron Pill Setback End of the Road for LLY's Obesity Plans?  Yahoo FinancePhysician Views Results: Physicians largely shrug off investors' concerns about next jewel in Lilly's obesity crown  FirstWord PharmaLilly orforglipron oral GLP-1 phase 3 weight loss trial  drugdiscoverytrends.comOrforglipron Shows Positive Efficacy, Tolerability in Weight Management  Pharmacy Times...

Original

Categories: Health | Obesity

Tags: a | cnbc | data | end | for | in | investors | loss | remains | results | shows | the | times | to | wegovy



Let us know what you think!

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

Leave a Comment

Scroll back to top